8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Bortezomib-based regimens used as induction in newly diagnosed multiple myeloma (ndMM) patients eligible for stem cell transplantation (SCT) the cost-utility analysis

      Read this article at

      ScienceOpen
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Economics of health & social care, Economics

          Comments

          Comment on this article